NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 129 filers reported holding NURIX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $186,730 | -17.1% | 23,757 | +5.3% | 0.00% | 0.0% |
| Q2 2023 | $225,304 | +13.3% | 22,553 | +0.7% | 0.00% | 0.0% |
| Q1 2023 | $198,868 | -17.5% | 22,395 | +2.0% | 0.00% | -50.0% |
| Q4 2022 | $241,000 | -16.0% | 21,949 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $287,000 | +9.1% | 22,028 | +6.1% | 0.00% | 0.0% |
| Q2 2022 | $263,000 | +20.6% | 20,752 | +33.5% | 0.00% | +100.0% |
| Q1 2022 | $218,000 | -54.8% | 15,550 | -6.6% | 0.00% | -50.0% |
| Q4 2021 | $482,000 | -6.2% | 16,644 | -2.9% | 0.00% | -33.3% |
| Q3 2021 | $514,000 | +10.3% | 17,142 | -2.3% | 0.00% | +50.0% |
| Q2 2021 | $466,000 | +7.4% | 17,550 | +25.8% | 0.00% | 0.0% |
| Q1 2021 | $434,000 | +94.6% | 13,953 | +106.0% | 0.00% | +100.0% |
| Q4 2020 | $223,000 | -3.9% | 6,772 | +2.0% | 0.00% | 0.0% |
| Q3 2020 | $232,000 | – | 6,641 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |